Ageing populations, complex diseases and their challenge to 21st century healthcare: the focus of the European Society for Pharmacogenomics and Theranostics.
作者信息
Henney Adriano
出版信息
Drug Metabol Drug Interact. 2011;26(2):43-4. doi: 10.1515/DMDI.2011.009.
PMID:21819265
Abstract
摘要
相似文献
1
Ageing populations, complex diseases and their challenge to 21st century healthcare: the focus of the European Society for Pharmacogenomics and Theranostics.
Drug Metabol Drug Interact. 2011;26(2):43-4. doi: 10.1515/DMDI.2011.009.
2
Drug metabolism and drug interactions and the European Society of Pharmacogenomics and Theranostics.
Drug Metabol Drug Interact. 2012;27(2):61. doi: 10.1515/dmdi-2012-0009.
3
The role of pharmacogenetics and pharmacogenomics in 21st-century medicine: state of the art and new challenges discussed in the VII Conference of the Spanish Pharmacogenetics and Pharmacogenomics Society (SEFF).
Drug Metab Pers Ther. 2016 Mar;31(1):1-2. doi: 10.1515/dmpt-2015-0033.
4
Report from the European Society of Pharmacogenomics and Theranostics (ESPT) Inaugural Symposium 2011 in Bled.
Drug Metabol Drug Interact. 2012;27(1):55-6. doi: 10.1515/dmdi-2012-0004.
5
Health systems in transition in Central and Eastern Europe.
J R Coll Physicians Edinb. 2004;34(4):305-12.
6
Pharmacogenomics: from cell to clinic.
Drug Metabol Drug Interact. 2013;28(3):133. doi: 10.1515/dmdi-2013-0035.
7
Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs.
Am J Manag Care. 2004 Jul;10(7 Pt 1):425-32.
8
How molecular medicine transforms policy (and everything else).
J Biolaw Bus. 2004;7(3):16-9.
9
Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education.
Pharmacogenomics J. 2005;5(4):221-5. doi: 10.1038/sj.tpj.6500312.
10
Pharmacogenomics: questions and concerns.
Curr Med Res Opin. 2005 Jul;21(7):1041-7. doi: 10.1185/030079905X50633.
Zotero 插件